ULTROMICS LIMITED

• ◆

  2 PSCs ceased in last 24 months

  Significant control changed hands — see the Ownership section.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +13.1%

  £1,351,051 → £1,527,696

• Cash

  -50.7%

  £11,885,319 → £5,860,435

• Net assets

  -1,111.8%

  -£1,388,787 → -£16,829,787

  lowest in 4 filed years

• Employees

  -2.7%

  75 → 73

• Operating profit

  +13.5%

  -£11,334,737 → -£9,802,688

• Profit before tax

  -30%

  -£12,842,226 → -£16,688,529

  lowest in 4 filed years

• Wages

  -7.9%

  £5,739,528 → £5,288,799

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

Grant Thornton UK LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As of 31 December 2024, the Consolidated Balance Sheet had cash reserves of £5.9m. Subsequent to the year end Ultromics raised $35m from its Series C transaction. In all cases, the group will have sufficient funds to meet its liabilities as they fall due during the 12 month period ending 30 June 2026, the going concern assessment period.”

Group structure

1. ULTROMICS LIMITED · parent
   1. Ultromics Inc. 100% · Atlanta, GA 30326 · provides sales services to Ultromics Limited being the exclusive distributor of the diagnostic tool in the US. Ultromics Inc also provides research and development support to Ultromics Limited.

Significant events

• “On 13 June 2025, the company exchanged on its Series C financing transaction raising $35m. On receipt of $30m of the total $35m the convertible loans will convert into Series C shares with the full $35m needing to be funded within 14 business days of exchange.”
• “In July 2025, the Group intends to pay employee bonuses (c. £282k excluding employer payroll taxes) in relation to the second half of 2024. This bonus is contingent on completion of the Series C fund-raise and as there was no legal or constructive obligation as at 31 December 2024 no accrual was included.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

14

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.